Company intelligence / Profile preview
Tonix Pharmaceuticals
Chatham, New Jersey, United Statestonixpharma.com ↗
- Ownership
- Public · TNXP
- Employees
- ~103
- Development stage
- Other
01
Overview
Tonix has submitted an NDA for TNX-102 SL for fibromyalgia with a PDUFA date of August 15, 2025. The company reported positive Phase 1 results for TNX-1500, their anti-CD40L mAb for kidney transplant rejection prevention. They also have a contract with the U.S. DoD's DTRA for up to $34 million to develop TNX-4200.
- Therapeutic areas
- PsychiatryRheumatologyImmunologyOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Small moleculesBiologicsVaccinesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
44 assets43 more assets in the full pipeline.
03
Partnerships
U.S. Department of DefenseDefense Threat Reduction AgencyUniversity of North CarolinaColumbia UniversityMakana Therapeutics
04
Financials
- Market cap
- $78.9M
- Total revenue
- $13.1M
- Enterprise value
- $-96.1M
Beyond the preview
Go deeper on Tonix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tonix Pharmaceuticals.